|
Diabetes Care, Vol 21, Issue 8 1221-1225, Copyright © 1998 by American Diabetes Association
Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects
GT Ko, JC Chan, VT Yeung, CC Chow, LW Tsang, JK Li, WY So, HP Wai and CS Cockram
Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong, China.
OBJECTIVE: To assess the validity of using fasting plasma glucose (FPG)
concentrations in conjunction with HbA1c or fructosamine for the screening
of diabetes in high-risk individuals. RESEARCH DESIGN AND METHODS: In this
study 2,877 Hong Kong Chinese (565 [19.6%] men; 2,312 [80.4%] women) with
various risk factors for glucose intolerance underwent a 75-g oral glucose
tolerance test (OGTT) for screening of diabetes. The risk factors included
a family history positive for diabetes, a history of gestational diabetes
or impaired glucose tolerance, and obesity. RESULTS: Using World Health
Organization (WHO) criteria, 1,593 (55.4%) had normal glucose tolerance,
657 (22.8%) had impaired glucose tolerance, and 627 (21.8%) had diabetes.
When the 1997 American Diabetes Association (ADA) criteria were applied,
394 (13.7%) had diabetes with an FPG > or = 7.0 mmol/l. Using multiple
receiver operating characteristic curve analysis, the paired values of an
FPG of 5.6 mmol/l and a HbA1c of 5.5% gave an optimal sensitivity of 83.8%
and specificity of 83.6% to predict a 2-h plasma glucose (PG) > or =
11.1 mmol/l. Likewise, the paired values of an FPG of 5.4 mmol/l and a
fructosamine level of 235 mumol/l (n = 2,408) gave an optimal sensitivity
of 81.5% and specificity of 83.2%. An FPG > or = 5.6 mmol/l and an HbA1c
> or = 5.5% was 5.4-fold more likely to occur in diabetic subjects
(based on the WHO criteria) compared with nondiabetic subjects. For paired
parameters less than these values, the likelihood ratio of this occurring
in diabetic subjects was only 0.11. Similarly, an FPG > or = 5.4 mmol/l
and a fructosamine > or = 235 mumol/l was fivefold more likely to occur
in diabetic subjects than in nondiabetic subjects, with both parameters
less than these values having a likelihood ratio of 0.04. Using these
paired values as initial screening tests, only subjects who had an FPG >
or = 5.6 mmol/l and < 7.8 mmol/l and an HbA1c > or = 5.5% (n = 642)
required an OGTT to confirm diabetes, thereby saving 77.7%
[(2,877-642)/2,877] of the OGTTs performed. Similarly, only subjects who
had an FPG > or = 5.4 mmol/l and < 7.8 mmol/l and a fructosamine >
or = 235 mumol/l (n = 526) required OGTT to confirm diabetes, meaning that
78.2% [(2,408-526)/2,408] of the OGTTs could have been saved. Based on the
1997 ADA criterion of an FPG cutoff value of 7.0 mmol/l, the corresponding
numbers of OGTTs to be saved were 82.6% and 85.5%, respectively.
CONCLUSIONS: The paired values of FPG and HbA1c or FPG and fructosamine
helped to identify potentially diabetic subjects, the diagnosis of which
could be further confirmed by the 75-g OGTT. Using this approach
approximately 80% of OGTTs could have been saved, depending on the
diagnostic cutoff value of FPG.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Likhari, T S Aulakh, B. M Singh, and R Gama
Does HbA1C predict isolated impaired fasting glycaemia in the oral glucose tolerance test in subjects with impaired fasting glycaemia?
Ann Clin Biochem,
July 1, 2008;
45(4):
418 - 420.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Doi, M. Kubo, T. Ninomiya, K. Yonemoto, M. Iwase, H. Arima, J. Hata, Y. Tanizaki, M. Iida, and Y. Kiyohara
Impact of Kir6.2 E23K Polymorphism on the Development of Type 2 Diabetes in a General Japanese Population: The Hisayama Study
Diabetes,
November 1, 2007;
56(11):
2829 - 2833.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bergeron, J. Yao, J. W. Woods, E. I. Zycband, C. Liu, Z. Li, A. Adams, J. P. Berger, B. B. Zhang, D. E. Moller, et al.
Peroxisome Proliferator-Activated Receptor (PPAR)-{alpha} Agonism Prevents the Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats: A Comparison with PPAR{gamma} Agonism
Endocrinology,
September 1, 2006;
147(9):
4252 - 4262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Shaw, P. Z. Zimmet, and K. G. M.M. Alberti
Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association Criterion
Diabetes Care,
May 1, 2006;
29(5):
1170 - 1172.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Expert Committee on the Diagnosis and Classificati
Follow-up Report on the Diagnosis of Diabetes Mellitus
Clin. Diabetes,
April 1, 2004;
22(2):
71 - 79.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Colagiuri, Z. Hussain, P. Zimmet, A. Cameron, and J. Shaw
Screening for Type 2 Diabetes and Impaired Glucose Metabolism: The Australian experience
Diabetes Care,
February 1, 2004;
27(2):
367 - 371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Follow-up Report on the Diagnosis of Diabetes Mellitus
Diabetes Spectr,
January 1, 2004;
17(1):
51 - 59.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
The Expert Committee on the Diagnosis and Classifi
Follow-up Report on the Diagnosis of Diabetes Mellitus
Diabetes Care,
November 1, 2003;
26(11):
3160 - 3167.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Anand, F. Razak, V. Vuksan, H. C. Gerstein, K. Malmberg, Q. Yi, K. K. Teo, and S. Yusuf
Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population
Diabetes Care,
February 1, 2003;
26(2):
290 - 296.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Krishnamurti and M. W. Steffes
Glycohemoglobin: A Primary Predictor of the Development or Reversal of Complications of Diabetes Mellitus
Clin. Chem.,
July 1, 2001;
47(7):
1157 - 1165.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. Perry, R. R. Shankar, N. Fineberg, J. McGill, and A. D. Baron
HbA1c Measurement Improves the Detection of Type 2 Diabetes in High-Risk Individuals With Nondiagnostic Levels of Fasting Plasma Glucose: The Early Diabetes Intervention Program (EDIP)
Diabetes Care,
March 1, 2001;
24(3):
465 - 471.
[Abstract]
[Full Text]
|
 |
|
Copyright © 1998 by the American Diabetes Association.
|
|
| |
|